CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life-threatening complications such as ventricular rupt...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Case reports 2023-06, Vol.15, p.101840, Article 101840
Main Authors: Ng, Choon Ta, Gonzalez Bonilla, Hilda M., Chang, Ian, Aung, M. Tun, Gile, Jennifer J., Pereira, Naveen L., Villasboas Bisneto, Jose C., Johnston, Patrick B., Villarraga, Hector R., Rodriguez-Porcel, Martin G., Lin, Grace, Lin, Yi, Herrmann, Joerg
Format: Article
Language:English
Subjects:
CAR-T
cardiac
cardio-oncology
cardiomyopathy
lymphoma
metastasis
Mini-Focus Issue: Cardio-Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life-threatening complications such as ventricular rupture, cardiac tamponade, and circulatory failure. We present a case series of patients with lymphoma and cardiomyopathy or cardiac metastasis managed with chimeric antigen receptor T-cell therapy. (Level of Difficulty: Advanced.) [Display omitted]
ISSN:2666-0849
2666-0849
DOI:10.1016/j.jaccas.2023.101840